CD56+/CD16- Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis

Jaime, P. (Universidad de Zaragoza) ; García-Guerrero, N. (Universidad de Zaragoza) ; Estella, R. ; Pardo, J. (Universidad de Zaragoza) ; García-Álvarez, F. (Universidad de Zaragoza) ; Martínez-Lostao, L. (Universidad de Zaragoza)

Resumen: Objective: Natural killer (NK) cells have been involved in the pathology of different inflammatory and autoimmune disorders. Inflammation is an important regulator of osteoarthritis (OA), but the molecular and cellular mechanisms regulating this process are not well defined. Design To understand the role of NK cells in OA, we have compared the phenotype (CD56 subsets and perforin and granzyme expression) and cytotoxic function of NK cells in peripheral blood and synovial fluid from patients with OA undergoing total knee arthroplasty.
Results: In contrast to peripheral blood lymphocytes (PBLs), the majority of NK cells from the synovial fluid were CD56brightCD16(-) cells. As expected the expression of the cytolytic mediators perforin and granzyme B in CD56brightCD16(-) cells was low and correlated with a poor cytotoxic potential against K562 sensitive target cells. Surprisingly, this low cytotoxic NK cell subset expressed high levels of granzyme A (a protease recently characterized as a key modulator of inflammation in mouse models) in synovial fluid but not in peripheral blood. The presence of the CD56(+)brightCD16(-) cells expressing granzyme A correlated with increased levels of pro-inflammatory cytokines in synovial fluid from OA patients.
Conclusion: Our results indicate that NK cells from the synovium of patients with OA, which present an immunoregulatory non-cytotoxic phenotype, show different phenotype comparing with NK cells from peripheral blood, especially expressing granzyme A, a pro-inflammatory molecule which may contribute to the establishment of chronic articular inflammation in this type of patients.

Idioma: Inglés

DOI: 10.1016/j.joca.2017.06.007

Año: 2017

Publicado en: Osteoarthritis and cartilage 25, 10 (2017), 1708-1718
ISSN: 1063-4584

Factor impacto JCR: 5.454 (2017)

Categ. JCR: RHEUMATOLOGY rank: 4 / 30 = 0.133 (2017) - Q1 - T1
Categ. JCR: ORTHOPEDICS rank: 2 / 77 = 0.026 (2017) - Q1 - T1

Factor impacto SCIMAGO: 2.497 - Biomedical Engineering (Q1) - Rheumatology (Q1) - Orthopedics and Sports Medicine (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA-FSE/B27
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/SAF2011-25390
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-1-R
Financiación: info:eu-repo/grantAgreement/EUR/TRAIN2/SOE2-P1-E-341

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Traumatología y Ortopedia (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)